US Edition
Zimmer Biomet Acquisition of Monogram Technologies to Expand Capacity in Robotics Devices
UNITED STATES, JUL 14 – Zimmer Biomet aims to lead orthopedic robotics with Monogram's AI-driven knee surgery platform, anticipating high-single-digit returns by year five and commercialization in early 2027.
- On July 14, 2025, Zimmer Biomet Holdings agreed to acquire all outstanding shares of Monogram Technologies for $4.04 per share upfront and a total equity value of $177 million.
- Facing competition, Zimmer Biomet plans to expand its surgical robotics portfolio, positioning itself as the first in orthopedics to offer a fully autonomous surgical robot and capture demand in the fast-growing medtech segment.
- After FDA clearance in March 2025, Monogram Technologies developed a CT-based, semi-autonomous, AI-navigated TKA robotic system, set to commercialize with Zimmer Biomet implants in early 2027.
- Financially, the acquisition is expected to be neutral to adjusted EPS from 2025 to 2027, before becoming accretive starting in 2028 and contributing to revenue growth beginning in 2027.
- In the broader market, the orthopedic robotics sector is projected to reach nearly $16 billion by 2030, according to Reuters cited GlobalData.
Insights by Ground AI
Does this summary seem wrong?
26 Articles
26 Articles
The Globe & Mail+8 Reposted by 8 other sources
Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions
Detailed price information for Zimmer Biomet Holdings (ZBH-N) from The Globe and Mail including charting and trades.
·Canada
Read Full ArticleCoverage Details
Total News Sources26
Leaning Left0Leaning Right1Center8Last UpdatedBias Distribution89% Center
Bias Distribution
- 89% of the sources are Center
89% Center
C 89%
11%
Factuality
To view factuality data please Upgrade to Premium
